DRI Healthcare Trust reported quarterly EPS of C$0.53, 44.2% below the C$0.95 estimate. But the miss came alongside company-reported growth in cash receipts and adjusted EBITDA, as well as a higher full-year outlook.
DRI Healthcare Trust (TSX: DHT.UN) released results after the market closed on November 4 for the quarter ended September 30, 2026. Calendar data shows earnings per unit of C$0.53, compared with an estimate of C$0.95. That’s a shortfall of C$0.42, or 44.2%.
Recent earnings trend
DRI Healthcare Trust
DHT-UN.TO
DHT-UN.TO
DRI Healthcare Trust
WealthAwesomeMarket cap
$1.08B
P/E
13.2x
Div. yield
0.53%
Div. / share
$0.10
52W high
$19.58
52W low
$14.61
1W change
+6.01%
Beta
0.54
Analyst Price Targets
Based on analyst covering DHT-UN · as of Nov 9, 2026
Wall Street analysts forecast DHT-UN stock price to rise 26.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$24.29
+26.3% Upside
Previously C$23.98 on Nov 6, 2026
Current Price
C$19.23
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DHT-UN's historical volatility
30-Day Vol
14.3%
Annualized
90-Day Vol
23.1%
Annualized
Trend (90d)
+18.1%
Annualized drift
90d Mean
C$20.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$19.65 | C$18.70 – C$20.64 |
| 60 trading days | C$20.08 | C$18.73 – C$21.52 |
| 90 trading days | C$20.51 | C$18.84 – C$22.34 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 4 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-03 | — | 0.5600 | — |
| 2026-09-30 | 2026-11-04 | 0.5300 | 0.9500 | -44.2% |
| 2026-06-30 | 2026-08-07 | 0.5600 | 0.6000 | -6.7% |
| 2026-03-31 | 2026-05-14 | 0.6800 | 0.5500 | +23.6% |
| 2025-12-31 | 2026-03-03 | 0.7800 | 0.5200 | +50.0% |
| 2025-09-30 | 2025-11-05 | 0.5500 | 0.5500 | +0.0% |
The company’s operating update was more positive. Its supplemental headlines report that normalized cash receipts and adjusted EBITDA each rose 9% year over year. DRI also expects 2026 adjusted EBITDA to exceed the high end of its previous US$157-million to US$162-million outlook. Follow results and market data on the DHT-UN.TO stock page.
Investor takeaway: The EPS miss was substantial, and DRI’s recent results have been mixed. It beat estimates in two of its last four comparable quarters, based on 23 quarters of actual-versus-estimate data. The reported 9% gains in cash receipts and adjusted EBITDA, along with the higher full-year EBITDA outlook, tell a different story from the EPS surprise. The available information doesn’t explain the gap, so investors should consider both signals rather than relying on either one alone.
C$0.53 EPS versus C$0.95 estimated
The 44.2% shortfall was the largest miss in the four most recent comparable quarters in the supplied history. DRI also missed estimates by 6.67% in the previous quarter, after beating them in the two quarters before that. The company-reported 9% growth in normalized cash receipts and adjusted EBITDA offers a more positive operating signal, but the available information doesn’t explain why EPS fell short.
Bull case
DRI reported 9% year-over-year growth in both cash receipts and adjusted EBITDA. Management also expects full-year adjusted EBITDA to exceed the high end of its previous outlook. The trust holds pharmaceutical royalties and recently announced a royalty purchase tied to tavapadon. Supplied fundamentals show a 29.59% profit margin and a 0.53% dividend yield. Analyst targets and the Wealth Awesome statistical forecast are above the supplied last close, but neither predicts future performance with certainty.
Bear case
EPS of C$0.53 came in well below the C$0.95 estimate, following another miss in the previous quarter. Estimates for the next period have fallen from C$0.57 to C$0.55 over the past 30 days, with two downward revisions and one upward revision. The consensus also points to a 7.1% year-over-year decline in estimated revenue. Royalty income depends in part on how the underlying medicines perform, and the supplied headlines don’t explain how EPS fell while adjusted EBITDA grew.
Analysis
DRI Healthcare Trust reported EPS of C$0.53 for the quarter ended September 30, compared with a calendar estimate of C$0.95. The 44.2% miss followed a 23.64% beat in March and a 6.67% miss in June. Before those two quarters, DRI beat estimates by 50% in December 2025. Across the last four comparable quarters, it has two beats and two misses.
The company’s release also reported a stronger operating picture. Normalized cash receipts rose 9% year over year to US$47.5 million, while adjusted EBITDA increased 9% to US$40.0 million. DRI said it expects 2026 adjusted EBITDA to exceed the high end of its previous US$157-million to US$162-million outlook. The available information doesn’t explain how these figures relate to the EPS result, so investors should assess the two signals separately.
DRI invests in pharmaceutical royalty interests, so cash receipts and the performance of the underlying medicines matter to its business. In September, the trust announced a US$316-million purchase of royalty rights tied to tavapadon, after the drug received FDA approval for Parkinson’s disease, according to the supplied headlines. The deal adds potential exposure, but the information here doesn’t show how much it may contribute in the future. See the DHT-UN.TO stock page for company and market data.
Analysis
For the next reported period, the supplied consensus estimate is C$0.55 EPS, based on four analysts. Estimates range from C$0.46 to C$0.68. The consensus is close to the year-ago EPS of C$0.55, while estimated revenue of US$45.30 million suggests a 7.1% year-over-year decline. The EPS estimate has slipped from C$0.57 over the past 30 days, with one upward revision and two downward revisions. These are forecasts, not reported results.
The supplied last close is C$19.23, above the 50-day moving average of C$17.95 and the 200-day average of C$17.33. It is also near the 52-week high of C$19.58. Recent market figures show gains of 2.45% over one day, 6.01% over one week and 5.37% over one month. These figures don’t show how the stock reacted to the earnings release in that session.
The analyst section lists an average target of C$24.29, 26.3% above the supplied last close. Its bullish label reflects the average target compared with the close. A formal rating isn’t available for Canadian listings. See the analyst targets section for details.
The Wealth Awesome price forecast is based on a statistical model and isn’t financial advice. Its 90-day mean is C$20.51, with a 68% range of C$18.84 to C$22.34 and a 95% range of C$17.30 to C$24.33. These are model estimates, not promises or recommendations.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
